| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02080078 Details | 2019-05-03 Interventional | 1 | 15 | Erlotinib Hydro… Theophylline Carcinoma, Non-… Advanced Solid … Non-small Cell … | REB decision - | |||
| NCT03805178 Details | 2019-05-02 Interventional | 2 | 0 | Abatacept Antibody-mediat… Lung Transplant… | Not activated at Duke - | |||
| NCT01276613 Details | 2019-05-02 Interventional | 1 | 18 | Gemcitabine Losartan Adenocarcinoma Pancreatic Canc… | Per memo from study team - | |||
| NCT02720484 Details | 2019-05-01 Interventional | 2 | 10 | Nivolumab Adrenocortical … Carcinoma Metastatic Carc… Recurrent Adren… Stage III Adren… Stage IV Adrena… | Study did not meet first stage requirements of interim analysis The study did not meet its first stage requirements of Interim analysis. | |||
| NCT01975389 2013-002795-41 Details | 2019-05-01 Interventional | 3 | 10564 | Bococizumab Cardiovascular … Cardiovascular … | See Detailed Description As specified in statistical analysis plan, due to discontinuation of the bococizumab clinical development program, health care resource utilization endpoints were not evaluated. | |||
| NCT01535937 Details | 2019-05-01 Interventional | 1/2 | 55 | Ketamine Midazolam Cocaine-Related… Cocaine Depende… | An analysis demonstrated that running the final participants was unnecessary. - | |||
| NCT01118351 Details | 2019-05-01 Interventional | 2 | 19 | Sunitinib Carcinoma Carcinoma, Tran… Urinary Bladder… Recurrent Bladd… Transitional Ce… | - Accrual to the study was suspended and trial was prematurely closed due to a predefined futility rule that was part of the study's initial statistical design. | |||
| NCT03669003 Details | 2019-04-30 Interventional | 2 | 0 | Gelatin Sponge,… Pneumothorax Pneumothorax Ia… | Will re-open at another time - | |||
| NCT03373305 Details | 2019-04-30 Interventional | 1 | 0 | Antibodies Antibodies, Mon… Antineoplastic … Brentuximab Ved… Immunoconjugate… Immunoglobulins Lenalidomide Piperidine Lymphoma Lymphoma, Non-H… Lymphoma, T-Cel… Lymphoma, T-Cel… Mycoses Mycosis Fungoid… Recurrence Sezary Syndrome CD30-Positive N… Folliculotropic… Recurrent Mycos… Recurrent Prima… Refractory Myco… Refractory Prim… | contract not executed - | |||
| NCT02943317 Details | 2019-04-30 Interventional | 1 | - | Avelumab Carcinoma, Ovar… Ovarian Neoplas… Epithelial Ovar… | The study was terminated upon completion of escalation phase, prior to opening expansion
cohorts - | |||
| NCT01712945 2011-005606-30 Details | 2019-04-30 Interventional | 1/2 | 40 | Alemtuzumab Multiple Sclero… Sclerosis | interim anlaysis failed: palifermin does not promote thymopoeisis after alemtuzumab - | |||
| NCT01878786 Details | 2019-04-26 Interventional | 2/3 | 25 | Everolimus Mycophenolic Ac… Tacrolimus Delayed Graft F… | Interim results suggested a concern for patient outcomes and safety The study was terminated prematurely and analysis was not performed on the incomplete data. | |||
| NCT01164956 Details | 2019-04-26 Interventional | 1 | 3 | Methylphenidate Fatigue Cancer | Insufficient Resources The study was terminated early due to insufficient resources. | |||
| NCT03439787 2017-005180-40 Details | 2019-04-25 Interventional | 4 | 15 | Bupivacaine Epinephrine Pain, Postopera… | Methodological problems/problems in the study design (competing pain and a placebo effect). No
serious adverse events or other safety issues - | |||
| NCT02021929 Details | 2019-04-25 Interventional | 2 | 28 | Sorafenib Hepatopulmonary… Syndrome | - Recruitment difficult due to challenges in screening for HPS, lack of patient awareness of HPS, and hesitation from potential subjects due to sorafenib side effects. Sample size reduced and sponsor terminated trial before reaching target sample size | |||
| NCT01148810 2008-006311-21 Details | 2019-04-25 Interventional | 2 | 18 | Siponimod Dermatomyositis Polymyositis | Trial was prematurely terminated due to enrollment challenges. The study was terminated due to new clinical data from overall BAF312 program (<10 mg/day already have optimal pharmacodynamic effect & clinical efficacy). There was no safety concern testing 10 mg BAF312 that would have required study termination. | |||
| NCT01858532 2012-005848-21 Details | 2019-04-24 Interventional | 3 | 5107 | Atrasentan Diabetic Nephro… Kidney Diseases Diabetic Nephro… | Strategic considerations - | |||
| NCT01467076 Details | 2019-04-24 Interventional | 2 | 7 | Alprostadil Hypertension, P… Respiratory Dis… Respiratory Dis… Respiratory Ins… Prematurity Pulmonary Hyper… | The study was halted due to futility concerns based on the unmet benchmarks as specified in the
pilot study protocol. - | |||
| NCT00704847 Details | 2019-04-24 Interventional | 3 | 1030 | Calcitonin Calcitonin Gene… Katacalcin Salmon calciton… Osteoarthritis Osteoarthritis,… | Male subjects were terminated due to an imbalance in prostate cancer events The study showed an underexposure to calcitonin compared to what was expected from phase I trials. | |||
| NCT03529331 Details | 2019-04-23 Interventional | 4 | 0 | Acetaminophen Acetaminophen, … Hydrocodone Morphine Oxycodone Pain | The ED physicians no longer prescribe opioids at discharge; not feasible to conduct the study - |